Halozyme Therapeutics (HALO) FY2014 results: revenue $75 million, up 37.5% on the year
Halozyme Therapeutics, Inc. (HALO) reported revenue of $75 million for fiscal 2014, the year ended 31 December 2014, up 37.5% on the year before. Net income was -$68 million, and diluted earnings per share $-0.56. The figures are the company's own, from the 10-K it filed with the SEC on 2 March 2015.
Revenue
$75 million
+37.5% on the year
FY2009FY2014
Operating margin
-83.7%
-146.8% a year earlier
FY2009FY2014
Net income
-$68 million
FY2009FY2014
Diluted EPS
-$0.56
FY2009FY2014
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Revenue
75.3
54.8
42.3
+37.5%
Cost of revenue
22.7
6.2
1.1
+264.0%
Gross profit
52.6
48.6
41.2
+8.3%
Gross margin
69.8%
88.6%
97.4%
Research and development
79.7
96.6
70.0
-17.5%
Selling, general and administrative
35.9
32.3
24.8
+11.1%
Operating income
-63.0
-80.4
-53.6
Operating margin
-83.7%
-146.8%
-126.7%
Interest expense
5.6
3.3
0.0
+70.5%
Pre-tax income
-68.4
n/a
n/a
Income tax
0.0
n/a
n/a
Net income
-68.4
-83.5
-53.6
Net margin
-90.8%
-152.3%
-126.5%
Diluted EPS
-$0.56
-$0.74
-$0.48
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Operating cash flow
-47.5
-49.3
-64.3
Capital expenditure
1.4
2.3
1.4
-40.5%
Free cash flow
-48.9
-51.6
-65.7
Free cash flow margin
-64.9%
-94.2%
-155.3%
Cash from investing
-33.0
-47.9
-1.4
Cash from financing
115
25.1
113
+356.8%
Depreciation and amortisation
1.8
1.2
1.1
+43.6%
Share-based compensation
15.3
9.5
8.3
+60.1%
Shares outstanding at period end
126m
115m
113m
+9.8%
Balance sheet
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Shareholders' equity
41.4
-20.0
48.9
Debt
49.9
49.8
29.7
+0.2%
Other liabilities
74.8
72.0
56.2
+3.8%
Total liabilities and equity
166
102
135
+63.1%
Fixed assets
3.0
3.4
3.7
-13.8%
Investments
74.2
44.1
0.0
+68.2%
Cash and equivalents
61.4
27.4
99.5
+124.4%
Receivables
9.1
9.1
15.7
+0.6%
Inventory
6.4
6.2
2.7
+3.8%
Other assets
11.8
11.6
13.2
+2.1%
Total assets
166
102
135
+63.1%
10-K for the year ended 31 December 2014, filed 2 March 2015: the filing.